New ceramide analogs 315 and 403 effectively reduce PEL proliferation in a dose-dependent manner. (A-B) The synthetic schemes for ceramide analogs 315 and 403. (C-F) KSHV⁺ PEL cell lines, BCBL-1 (C-D) and BCP-1 (E-F), were treated with the indicated concentrations of analog 315, 403, or vehicle for 48 hours. The cell proliferation status was then examined using the WST-1 Cell Proliferation Assay (Roche). Error bars represent SD for 3 independent experiments. (G) Comparison of 50% IC₅₀ of different compounds targeting sphingolipid metabolism in PEL cell lines. DCM, dichloromethane; THF, tetrahydrofuran.